Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Luteolin Nanocapsules Demonstrate Effective Anticancer Activity in Mouse Model

By BiotechDaily International staff writers
Posted on 23 Jan 2014
Image: Cellular uptake of nanoparticles encapsulating both dye and luteolin (Photo courtesy of Winship Cancer Institute of Emory University).
Image: Cellular uptake of nanoparticles encapsulating both dye and luteolin (Photo courtesy of Winship Cancer Institute of Emory University).
Nanocapsules containing the natural antioxidant luteolin were found to be significantly more effective than natural luteolin in inhibiting growth of cancer cells both in culture and in a mouse xenograft model.

Luteolin is a flavone, a type of flavonoid, and, like all flavonoids, has a yellow crystalline appearance. Dietary sources include celery, green pepper, thyme, dandelion, chamomile tea, carrots, olive oil, peppermint, rosemary, navel oranges, and oregano. Luteolin reportedly acts as a monoamine transporter activator, and is one of the few chemicals demonstrated to possess this property. Experiments have suggested that luteolin may inhibit the development of some types of skin cancer.

In the current study, investigators at Emory University (Atlanta, GA, USA) formulated water-soluble polymer-encapsulated Nano-Luteolin from luteolin, and studied its anticancer activity against lung cancer and head and neck cancer. The low water solubility of luteolin, which hampers its use in treatment due to problems of low bioavailability, poor systemic delivery, and low efficacy, led the investigators to choose a nanocapsule format for their experiments.

Results published in the January 2014 issue of the journal Cancer Prevention Research revealed that like luteolin, Nano-Luteolin inhibited the growth of lung cancer cells (H292 cell line) and squamous cell carcinoma of head and neck (SCCHN) cells (Tu212 cell line). In vivo studies using a tumor xenograft mouse model demonstrated that Nano-Luteolin had a significant inhibitory effect on the tumor growth of SCCHN in comparison to luteolin.

"Our results suggest that nanoparticle delivery of naturally occurring dietary agents like luteolin has many advantages," said senior author Dr. Dong Moon Shin, professor of hematology and medical oncology at Emory University. "By using a high concentration of luteolin in the blood, we were better able to inhibit the growth of cancer cells."

Related Links:

Emory University


Channels

Genomics/Proteomics

view channel
Image: An activated PTEN dimer that contains two non-mutant proteins (A) can transform the functional lipid (D) on the cellular membrane (E) into a chemical form that tunes down cancer predilection. Dimers that contain a mutated protein (B) or PTEN monomers cannot transform the functional lipid (Photo courtesy of Carnegie Mellon University).

PTEN Requires a Stable Dimer Configuration to Effectively Suppress Tumor Growth

Molecular structural analysis has shown that the PTEN (phosphatase and tensin homolog) tumor suppressor can function effectively only when two wild-type alleles are present to form a stable dimer that... Read more

Lab Technologies

view channel
Image: The ChilliBlock modular system for precise, controlled cooling and heatingof biological samples (Photo courtesy of Asynt).

Modular Cooling/Heating System Safeguards Temperature-Sensitive Biological Samples

A new modular system designed for precise, controlled cooling and heating of biological samples in microplates, vials and Eppendorf tubes is now available for biotech, clinical, and life science laboratories.... Read more

Business

view channel

MS Drug Deal to Net More Than USD 1 Billion

A pharmaceutical company based in Switzerland has purchased the remaining rights to the multiple sclerosis drug Ofatumumab, which will allow it to continue development of the compound for treating relapsing remitting multiple sclerosis (RRMS) and similar autoimmune diseases. Novartis (Basel, Switzerland) recently announced... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.